Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (9r,13s)-13-(4-(5-chloro-2-(4-chlorotriazol-1-yl)phenyl)-6-oxopyrimidin-1-yl)-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo(12.3.1.02,6)octadeca-1(18),2(6),4,14,16-pentaen-8-one
2. Bms-986177
3. Jnj-70033093
1. 1802425-99-5
2. Milvexian [usan]
3. Bms-986177
4. Jnj-70033093
5. 0w79ndq608
6. Milvexian (usan)
7. Bms 986177
8. (5r,9s)-9-(4-(5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6h)-yl)-21-(difluoromethyl)-5-methyl-21h-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one
9. (9r,13s)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
10. Milvexian [inn]
11. Unii-0w79ndq608
12. Chembl4112929
13. Schembl16982989
14. Gtpl11754
15. Ex-a6455
16. Bms986177
17. Who 11401
18. Jnj70033093
19. Compound 17 [pmid: 34494428]
20. Ac-36903
21. Hy-125856
22. Cs-0101887
23. D11802
24. (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxopyrimidin-1(6h)-yl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-15,11-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
25. (9r,13s)-13-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
26. 11,15-metheno-15h-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6h)-one, 10-(4-(5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6h)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6r,10s)-
27. 11,15-metheno-15h-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6h)-one, 10-(4-(5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6h)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6r,10s)-2
28. Bms-986177; (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxopyrimidin-1(6h)-yl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-15,11-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
29. Yxg
| Molecular Weight | 626.4 g/mol |
|---|---|
| Molecular Formula | C28H23Cl2F2N9O2 |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 4 |
| Exact Mass | 625.1319827 g/mol |
| Monoisotopic Mass | 625.1319827 g/mol |
| Topological Polar Surface Area | 123 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 1100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
BMS-986177 (milvexian) is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) which delays the time to clot formation, decreases fibrin incorporation into the clot, and reduces the resistance of clots to fibrinolysis.
Lead Product(s): Milvexian,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 25, 2023
Lead Product(s) : Milvexian,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986177 (milvexian) is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) which delays the time to clot formation, decreases fibrin incorporation into the clot, and reduces the resistance of clots to fibrinolysis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2023
Details:
Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.
Lead Product(s): Milvexian,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 07, 2023
Lead Product(s) : Milvexian,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2023
Details:
Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Coronary Syndrome.
Lead Product(s): Milvexian,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2023
Lead Product(s) : Milvexian,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Coronary Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2023
Details:
BMS-986177 (milvexian) is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) which delays the time to clot formation, decreases fibrin incorporation into the clot, and reduces the resistance of clots to fibrinolysis.
Lead Product(s): Milvexian,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 02, 2023
Lead Product(s) : Milvexian,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986177 (milvexian) is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) which delays the time to clot formation, decreases fibrin incorporation into the clot, and reduces the resistance of clots to fibrinolysis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2023
Details:
Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Milvexian,Midazolam,Ethinyl Estradiol,Drospirenone
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 31, 2023
Lead Product(s) : Milvexian,Midazolam,Ethinyl Estradiol,Drospirenone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Milvexian in Healthy Adult Females
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 31, 2023
Details:
Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ischemic Stroke.
Lead Product(s): Milvexian,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2023
Lead Product(s) : Milvexian,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ischemic Stroke.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2023
Details:
JNJ-70033093 (milvexian) is a potential first-in-class oral factor XIa (FXIa) inhibitor (anti-thrombotic) being studied for the prevention and treatment of major thrombotic conditions.
Lead Product(s): Milvexian,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2022
Lead Product(s) : Milvexian,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JNJ-70033093 (milvexian) is a potential first-in-class oral factor XIa (FXIa) inhibitor (anti-thrombotic) being studied for the prevention and treatment of major thrombotic conditions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2022
Details:
Milvexian demonstrated efficacy and no increase in bleeding across doses, when compared with enoxaparin, for postoperative venous thromboembolism (VTE) prevention in patients undergoing elective total knee replacement (TKR) surgery.
Lead Product(s): Milvexian,Inapplicable
Therapeutic Area: Orthopedics/Orthopedic Surgery Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Johnson & Johnson Innovative Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2021
Lead Product(s) : Milvexian,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Milvexian demonstrated efficacy and no increase in bleeding across doses, when compared with enoxaparin, for postoperative venous thromboembolism (VTE) prevention in patients undergoing elective total knee replacement (TKR) surgery.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 15, 2021
Details:
BMS-986177 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Milvexian,14-C BMS-986177
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 16, 2021
Lead Product(s) : Milvexian,14-C BMS-986177
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986177 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 16, 2021
Details:
Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Milvexian,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2021
Lead Product(s) : Milvexian,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
4-[5-Chloro-2-[4-(trimethylsilyl)-1H-1,2,3-triazol...
CAS Number : 1802430-53-0
End Use API : Milvexian
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
6-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phen...
CAS Number : 1802430-55-2
End Use API : Milvexian
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phen...
CAS Number : 1802430-54-1
End Use API : Milvexian
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
N-[(1S)-1-(4-chloro-2-pyridinyl)-3-buten-1-yl]-, 1...
CAS Number : 1329171-69-8
End Use API : Milvexian
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
52
PharmaCompass offers a list of Milvexian API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Milvexian manufacturer or Milvexian supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Milvexian manufacturer or Milvexian supplier.
PharmaCompass also assists you with knowing the Milvexian API Price utilized in the formulation of products. Milvexian API Price is not always fixed or binding as the Milvexian Price is obtained through a variety of data sources. The Milvexian Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Milvexian manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Milvexian, including repackagers and relabelers. The FDA regulates Milvexian manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Milvexian API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Milvexian supplier is an individual or a company that provides Milvexian active pharmaceutical ingredient (API) or Milvexian finished formulations upon request. The Milvexian suppliers may include Milvexian API manufacturers, exporters, distributors and traders.
Milvexian Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Milvexian GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Milvexian GMP manufacturer or Milvexian GMP API supplier for your needs.
A Milvexian CoA (Certificate of Analysis) is a formal document that attests to Milvexian's compliance with Milvexian specifications and serves as a tool for batch-level quality control.
Milvexian CoA mostly includes findings from lab analyses of a specific batch. For each Milvexian CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Milvexian may be tested according to a variety of international standards, such as European Pharmacopoeia (Milvexian EP), Milvexian JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Milvexian USP).
